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FLIPping the kill switch
I
t’s always wise to consult others 
before making a big decision, so a 
cell seeks input from a lot of different 
proteins before choosing between survival 
and death by apoptosis. Fricker et al. 
describe how one particular protein—
cFLIP—can nudge a cell in either direc-
tion depending on the expression levels of 
its three different isoforms (1).
Cells contemplate suicide in response 
to a number of stimuli, including activa-
tion of the CD95 death receptor by its ex-
tracellular ligand CD95L (2). Receptor 
stimulation triggers the formation of a 
death-inducing signaling complex (DISC) 
at the plasma membrane containing inac-
tive procaspase-8 molecules, which are 
converted by a series of self-cleavage 
events into active proteases that induce 
apoptosis (3). cFLIP, which exists as one 
long (cFLIP  L  ) and two short (cFLIP  S/R  ) 
splice variants, also localizes to the DISC 
and regulates the activation of procaspase-8. 
The short variants inhibit procaspase-8 
cleavage and cell death, but the function 
of cFLIP  L   is more controversial: while 
some reports suggest cFLIP  L   is exclu-
sively anti-apoptotic (4), others indicate 
that the longer isoform can promote apop-
tosis under certain conditions (5).
Inna Lavrik and colleagues at the Ger-
man Cancer Research Center in Heidelberg 
decided to take a more quantitative approach 
to the problem. “Previous studies simply 
overexpressed or down-regulated cFLIP,” 
explains Lavrik. “Ours is the fi  rst quantita-
tive study to really show the conditions in 
which cFLIP  L   promotes apoptosis.”
Fricker et al. found that cFLIPL could 
either block or accelerate procaspase-8 
processing and cell death depending on its 
expression level and the strength of CD95 
stimulation. The researchers then measured 
the absolute concentrations of all the im-
portant proteins known to function at the 
DISC in HeLa cells and generated a math-
ematical model describing how cFLIP in-
fl  uences the cell’s life-and-death decision. 
The approach revealed a narrow window in 
which intermediate amounts of cFLIPL 
boost procaspase-8 cleavage and apoptosis. 
Nevertheless, says Lavrik, the results 
show that “the same molecule can have 
different functions in a signaling pathway, 
depending on its own concentration and 
the concentration of other proteins in the 
same pathway.”
The reason for this seems to lie in two 
opposing properties of cFLIP  L  . Like its 
shorter variants, cFLIP  L   has a high affi  nity 
for the DISC and competes with procas-
pase-8 for recruitment to the death receptor 
complex. Thus, at high concentrations, all 
cFLIP isoforms block procas-
pase-8’s activation at the 
DISC. Unlike cFLIP  S/R   how-
ever, cFLIP  L   can form a cata-
lytically active heterodimer 
with procaspase-8 in which 
cFLIP  L   stabilizes the pro-
tease’s active loop. Therefore 
at intermediate concentra-
tions cFLIP  L   stimulates pro-
caspase-8 processing without blocking its 
recruitment to the DISC. The opportunity 
for cFLIP  L   to accelerate cell death is expand-
ed if the CD95 death receptor is strongly 
stimulated by its ligand: more DISCs are 
induced, making it harder for cFLIP  L   to 
completely block procaspase-8 recruitment.
The amounts of the shorter cFLIP iso-
forms also infl  uence  cFLIP  L  ’s effects: 
when cFLIP  S/R   levels are high, the amount 
of procaspase-8 processing at the DISC is 
so low that any stabilization of the protease 
by cFLIP  L   will greatly accelerate the en-
zyme’s activation and subsequent apoptosis. 
The choice between life and death is thus a 
complex decision involving the different 
cFLIP isoforms and the strength of CD95 
activation. “It depends on the ratio of all 
these proteins at the DISC,” says Lavrik.
Tweaking the levels of these proteins 
can therefore have a major impact—tumor 
cells are known to regulate CD95 sig-
naling by changing the relative expression 
of long and short cFLIP 
isoforms. Lavrik now wants 
to transfer her model from 
HeLa to cancer cells, which 
may use additional proteins 
to regulate the outcome of 
life-and-death decisions. 
“The model nicely explains 
our data on all known com-
ponents in HeLa cells,” 
says Lavrik. “But there may be other 
modulators in different cell types, which 
we’re trying to identify through various 
screening procedures.”
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Nicolai Fricker (middle), Inna Lavrik (sec-
ond from left), and colleagues quantify 
components of the CD95 death-inducing 
signaling complex and generate a math-
ematical model to explain the complex 
effects of cFLIP isoforms on procaspase-8 
activation and apoptosis. A long splice 
variant, cFLIP  L  , can either promote or 
inhibit cell death depending on its own 
concentration, the amounts of shorter cFLIP 
isoforms, and the strength of signaling 
by the CD95 death receptor. The graph 
shows the model’s experimentally veri-
ﬁ  ed prediction that only an intermediate 
amount of cFLIP  L   will boost procaspase-8 
activation (indicated by warmer colors), 
while higher cFLIP  L   concentrations inhibit 
the initiation of cell death.
“The same 
molecule can 
have different 
functions in 
a signaling 
pathway.”
The amounts of different cFLIP isoforms help cells choose between life and death.
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